You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of monoclonal antibody-mediated interventions to combat malaria

    SBC: SANARIA INC.            Topic: 109

    This contract is to provide proof of concept studies for the development of a monoclonal antibody to combat P. falciparum malaria.

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. System for the Large-scale Production of Membrane Proteins

    SBC: Athena Environmental Sciences Inc            Topic: 400

    Membrane proteins play a fundamental and critical role in cellular processes. Their direct link to human disease as well as their key role in signal transduction, has made many membrane proteins the foremost targets for chemotherapeutic intervention with more than 50% of all drugs designed to modulate the activity of this class of proteins. Despite this central role in human health, the biochemica ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. RestEaze: A Novel Wearable Device and Mobile Application to Improve the Diagnosis and Management of Restless Legs Syndrome in Patients with Alzheimer's Disease

    SBC: TANZEN MEDICAL, INC.            Topic: NIA

    Project Abstract Millions of patients with Alzheimer’s disease (AD) suffer from sleep disturbances that significantly degrade their quality of life and amplifies the heavy emotional burden on caregivers. Restless Legs Syndrome (RLS) is likely a factor for the sleep disturbance in these patients, however, RLS is currently difficult to diagnose, particularly in patients with AD. The diagnosis is m ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The aim of this project is to conduct a pivotal clinical trial of Sanaria’s Plasmodium falciparum (Pf) whole sporozoite (SPZ) vaccine, Sanaria® PfSPZ Vaccine, to support licensure for travelers. This is an important step toward licensure for the underserved populations who need it most, especially in Africa. The urgency of developing a malaria vaccine has been highlighted by COVID-19. ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)

    SBC: FZATA INC            Topic: 300

    Abstract Ulcerative colitis and Crohn’s disease are major forms of inflammatory bowel disease (IBD), which is characterized by chronic intestinal inflammation and gut microbiota dysbiosis. IBD has been associated with poor quality of life and often results in complications requiring hospitalizations and surgical procedures that causes significant morbidity and financial losses in the US. In past ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. EC1 is a mobile 360-degree point-of-view learning and gamification tool integrating a VR scenario, APIE response procedures and assessment to test and improve firefighter decision-making and response.

    SBC: MetaMedia Training International, Inc.            Topic: NIEHS

    Abstract Hazardous material releases pose a serious threat to our communities. In 2018, the Stakeholder Preparedness Review (SPR) found that 50% of states and territories identified chemical and radiological hazardous material releases, the most frequently cited ‘technological hazard’ was a troubling concern (FEMA, 2019). In 2019, the Department of Transportation reported an all-time high 22,7 ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Commercialization of Low-Cost Portable 3D Ultrasound for Surveillance of Arteriovenous Fistula Maturation by Point-of-Care Dialysis Clinicians

    SBC: SONAVEX INC            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Severe kidney disease accounts for 7% of all Medicare and Medicaid costs. The most cost-effective way to perform dialysis uses an arteriovenous fistula to connect to dialysis machines, but fistula use is limited by the malfunctions immediately following creation (maturation failure), which can render up to 70% of all created fistulas unusable. Ultrasound monitoring of the ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Full-length sequencing of individual RNAs from heterogeneous samples

    SBC: Phaeno Inc            Topic: 172

    Summary Despite large investments in nucleic acid technology, the ability to sequence large numbers of full-length individual RNAs, from complex samples, with highest accuracy, has remained out of reach. Pheno introduces an advance for large scale Next Generation DNA Sequencing (NGS) sequencing of effectively unlimited numbers of individual RNA molecules from heterogeneous mixtures. We seek to pro ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile Three-Dimensional Screening for Cranial Malformations

    SBC: PEDIAMETRIX INC.            Topic: NIDCR

    ABSTRACTDelayed identification of infant head malformation is causing unnecessary medical complications and societal costs. A critical challenge in the early detection is the absence of tools available to pediatric offices to perform quantitative head shape assessment during well-child visits. Delays in diagnosis limit the opportunity for early, less invasive and effective treatment options. In th ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation

    SBC: GLYCOT THERAPEUTICS LLC            Topic: 300

    Project abstract/summary In the proposed research, GlycoT will employ its proprietary chemoenzymatic glycan-remodeling platform to establish a facile, robust, and scalable site-specific antibody conjugation technology. Conjugation of various functional molecules to antibodies are frequently used for a wide variety of applications within the life science sectors, such as fluorescent labeled antibod ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government